September 2022 layoffs.

Quote


















anonymous said:
So i guess you were surprised and very pleased, unless you're one of the negative Teva hating trolls that comes on here?
Click to expand...
It’s good news that the opioid litigation is sorted albeit at slightly higher cost than anticipated. The business is still struggling though and it would be silly to pretend otherwise.
 


















So, to those who profess a restructuring with just rhetoric. HOW about posing the question "Will there be a restructuring" this year at the town hall meeting. If you write the question prior to the meeting for submittal it probably will not be addressed. Ask it and wait for the answer then you would have what's needed validate your endless doomsday rhetoric.
 






anonymous said:
So, to those who profess a restructuring with just rhetoric. HOW about posing the question "Will there be a restructuring" this year at the town hall meeting. If you write the question prior to the meeting for submittal it probably will not be addressed. Ask it and wait for the answer then you would have what's needed validate your endless doomsday rhetoric.
Click to expand...
I’ll be too busy giving management reacharounds
 






OP here...OK folks, by now you've seen the numbers. Austedo 154m in Q1, 204m in Q. Tracking for 225m in Q3. Another year not hitting a billion dollars. True forecasts are just under 900 million. While that is nice, the growth trajectory has all but stopped and the man (woman)-power behind this drug is dragging down profits. Our margins are much thinner than Neurocrine's for the VMAT franchise too. It's not good here in NJ and major changes are continuing as originally planned. Will keep you posted but still looking at a september/october reorg.
 












anonymous said:
That's it? No update on uzedy progress?
Weak
Click to expand...

You need to understand that Uzedy has nothing to do with this equation. If it happens (approval) it happens and whatever is left of that original sales force will be blended in with the NeuroPsych sales teams. The person saying, "OP Here" is a blow hard posing as someone from Parsippany just trying to stir the pot. Yes, a re-alignment of territory footprints and team size of NeuroPsych and NeuroScience is inevitable and that will probably start taking place in late October / early November. Ajovy will be moved to even a smaller ratio of product weighting for the Neuroscience teams while still having a voice with Austedo in Neurology. NeuroPsych will stay as the dominant voice with Austedo and have Uzedy in a 2nd position. Teva needs to be leaner on headcount in the field over the next 3-5 years in order to get this debt paid down to respectable levels for investors. Stock is already rebounding a bit with the recent news of a national opioid settlement and with Austedo being profitable, things could start turning around quicker than most think.
 






Teva is poked , I’ll come to realise no one wants to hear the truth including our senior executives , the only option for everyone is whether the gloryhole or the reacharound is the best course of action to survive in this poorly run company
 






Austedo 204m and Ingrezza 350m in q2. The gap is widening folks. This can’t end well. More share of voice and getting beat even worse. I hate Teva. I hate my job. I hate Austedo.
 










































OP here...I have all but secured employment elsewhere (probably six weeks out). I'm keeping my fingers crossed I get laid off and the severance check comes first. As I stated before, I fully expect to be severed and sadly a lot of you in the field will as well. Nobody believed me when I tried to share this news earlier, now you see there's a hiring freeze, reps crawling over each other, not getting the ROI on Austedo, Ajovy's margins are horrible etc. Reorg is looking more like October vs September but it's coming. Uzedy may be added to the bag of one sales team carrying Austedo and Uzedy but that wouldn't be until next year sometime anyways. Uzedy delay hurts its chances of hitting initial sales goals for it, and that's if it even gets approved. I'll try and keep you all in the know.
 






Top Bottom
Back
Quote